Healthcare

Ramsay Health Care Limited(ASX:RHC) was among theASX 200 gainers on 14 April, supported by renewed investor confidence following its latest half-year results. The stock recorded a significant spike in trading activity, with volume at approximately777,850 shares, representing a146% increase above its 90-day average volume.

The broader healthcare and biotech sector has faced selling pressure in recent months amid concerns about rising interest rates, inflation, and the impact on healthcare valuations across the industry. Investors typically favor more conservative positions when rates are rising and economic uncertainty increases, which …

The S&P/ASX 200 Health Care Index (XHJ) fell on 14 April 2026, losing 296.4 points or 0.68 per cent to close at approximately 43,210. The decline was driven by weakness in the sector's heavyweight constituent CSL Ltd, which accounts for a dominant share of …

Clarity Pharmaceuticals Ltd (ASX:CU6) is an Australian clinical-stage biotechnology company developing a pipeline of copper-based theranostic radiopharmaceuticals — a class of drugs that combine diagnostic imaging and therapeutic treatment in a single molecule. The company's proprietary SAR Technology platform uses copper isotopes (including copper-64 …

EMVision Medical Devices Limited (ASX:EMV) experienced a minor share price decline of 1.61%, closing atAUD 1.53on 13 April 2026, despite a fundamentally positive quarterly activities report. The stock has faced a challenging year, remaining down 18.62% over the past 12 months. However, the latest …

The gap between the current price and the broker target of approximately 49% is unusually wide for a large-cap healthcare company of CSL's quality and reflects a market that is grappling with the complexity of the company's current transformation phase. The first half of …

The stock currently trades at AUD 173.33, having gained AUD 1.23 or 0.71% in the most recent session, with a market capitalisation of AUD 11.25 billion. Against a broker Buy target of AUD 250.27 (As per EODHD/Others consensus rating), the implied upside of approximately …